TP53 and cancer: Consistently, PI3K inhibitor LY294002 reduces MDM4 levels in a range of cancer cells with wt p53 (U2OS, LNCap, and OVCA420), associated with an increase in p21 levels (Lopez-Pajares et al., 2008).